Shares of Novo Nordisk plummeted Tuesday after the company issued a disappointing sales forecast for 2026, triggering investor concerns. The Wegovy maker anticipates an adjusted sales growth of -5% to -13% at constant exchange rates (CER) for 2026. This starkly contrasts with the 10% sales growth reported in 2025, signaling potential headwinds for the pharmaceutical giant.

The lower outlook stems from several factors. These include anticipated price reductions due to the "Most Favoured Nations" agreement in the U.S., the upcoming patent expiry of the semaglutide molecule in certain markets, and increasing competition within the industry. This news also impacted shares of rival Eli Lilly, suggesting a broader impact on the weight-loss drug market.

In 2025, Novo Nordisk's sales reached DKK 309.1 billion, and operating profit increased by 6% at CER, excluding a company-wide transformation. The company is a leader in the treatment of diabetes and obesity. The revised outlook raises questions about the company's future growth trajectory and its ability to maintain its market dominance.

Investors are now closely watching Novo Nordisk's strategic responses to these challenges. The company needs to navigate pricing pressures, patent expirations, and heightened competition to protect its market share. Further details on these strategies and how they will impact future earnings will be key for shareholders.